ATE556707T1 - Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits - Google Patents

Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits

Info

Publication number
ATE556707T1
ATE556707T1 AT04759288T AT04759288T ATE556707T1 AT E556707 T1 ATE556707 T1 AT E556707T1 AT 04759288 T AT04759288 T AT 04759288T AT 04759288 T AT04759288 T AT 04759288T AT E556707 T1 ATE556707 T1 AT E556707T1
Authority
AT
Austria
Prior art keywords
inhibitors
phosphodiesesterase
treatment
cognitive deficit
cognitive
Prior art date
Application number
AT04759288T
Other languages
English (en)
Inventor
Timothy Tully
Filippo Cavalieri
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE556707T1 publication Critical patent/ATE556707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Magnetic Ceramics (AREA)
AT04759288T 2003-04-08 2004-04-08 Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits ATE556707T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training
PCT/US2004/010876 WO2004091609A2 (en) 2001-08-10 2004-04-08 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Publications (1)

Publication Number Publication Date
ATE556707T1 true ATE556707T1 (de) 2012-05-15

Family

ID=37416211

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759288T ATE556707T1 (de) 2003-04-08 2004-04-08 Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits

Country Status (7)

Country Link
US (2) US20040224316A1 (de)
EP (4) EP2340831B1 (de)
JP (1) JP4833834B2 (de)
AT (1) ATE556707T1 (de)
CA (1) CA2521839C (de)
ES (3) ES2403283T3 (de)
WO (1) WO2004091609A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
DK1355669T3 (da) * 2000-08-10 2011-11-21 Cold Spring Harbor Lab Forbedret kognitiv træning
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
EP2377533A3 (de) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase-4-Hemmer für kognitive und motorische Rehabilitation
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
JP2010521444A (ja) * 2007-03-12 2010-06-24 バイオリポックス エービー 炎症の治療において有用なピペリジノン類
CN101808647A (zh) * 2007-05-15 2010-08-18 海利空医疗公司 通过抑制Gpr12治疗认知障碍的方法
CA2684879A1 (en) * 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering rna (sirna)
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
CN102143749A (zh) * 2008-07-18 2011-08-03 达特神经科学有限责任公司 评估记忆药剂的方法和系统
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
EP3125900A1 (de) * 2014-03-28 2017-02-08 Algiax Pharmaceuticals GmbH Behandlung von kognitiven störungen
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
WO2022156727A1 (zh) 2021-01-21 2022-07-28 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
CA2133566A1 (en) 1992-04-10 1993-10-11 Charles P. Emerson, Jr. Transcription control element for increasing gene expression by myoblasts
MX9701600A (es) * 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
EP0781335A1 (de) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Klonierung und karakterisierung von genen die mit einem langzeitgedächtnis assoziert sind
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
DK0936923T3 (da) * 1996-11-15 2004-04-26 Kennedy Inst Of Rheumatology Undertrykkelse af TNFalpha og IL-12 ved terapi
AU735934B2 (en) * 1997-01-15 2001-07-19 Altana Pharma Ag Phthalazinones
CA2343732C (en) 1998-09-09 2009-06-16 Inflazyme Pharmaceuticals Ltd. Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
EP1157007A1 (de) 1999-02-25 2001-11-28 Merck Frosst Canada Inc. Pde-iv hemmende verbindungen, zusammensetzungen und verfahren zur herstellung
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU4215801A (en) 2000-03-16 2001-09-24 Inflazyme Pharm Ltd Benzylated pde4 inhibitors
DK1355669T3 (da) * 2000-08-10 2011-11-21 Cold Spring Harbor Lab Forbedret kognitiv træning
ES2344411T3 (es) * 2002-08-19 2010-08-26 Helicon Therapeutics, Inc. Metodos de escrutinio para potenciadores cognitivos.

Also Published As

Publication number Publication date
CA2521839C (en) 2014-08-05
EP2340831A1 (de) 2011-07-06
US20060247252A1 (en) 2006-11-02
EP2156831B1 (de) 2013-02-27
ES2403333T3 (es) 2013-05-17
ES2403283T3 (es) 2013-05-17
EP1631281A2 (de) 2006-03-08
EP2116240B1 (de) 2013-02-27
US20040224316A1 (en) 2004-11-11
EP2156831A1 (de) 2010-02-24
CA2521839A1 (en) 2004-10-28
ES2509093T3 (es) 2014-10-17
HK1087351A1 (en) 2006-10-13
WO2004091609A3 (en) 2007-08-16
EP1631281B1 (de) 2012-05-09
JP4833834B2 (ja) 2011-12-07
EP2116240A1 (de) 2009-11-11
HK1159514A1 (en) 2012-08-03
US8097647B2 (en) 2012-01-17
WO2004091609A2 (en) 2004-10-28
JP2006524243A (ja) 2006-10-26
EP2340831B1 (de) 2014-09-10

Similar Documents

Publication Publication Date Title
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
WO2005048953A3 (en) Amide derivatives as kinase modulators
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE60122368D1 (de) Verwendung von Gaboxadol zur Behandlung von premenstruelle Störung, postnatal Depression oder postmenopausal-bedingte-dysphorische Störung
DE602006004009D1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE602004025808D1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60231507D1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
EP1663283A4 (de) Glutamin zur verwendung bei der behandlung von verletzungen
WO2007028151A3 (en) Surgical devices and related methods thereof
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson